Development and Validation of a Stability-Indicating RP-HPLC Method for the Quantitative Estimation of Balofloxacin in Bulk Drug and Pharmaceutical Tablet Dosage Forms

The pharmaceutical industry places significant emphasis on ensuring the quality, safety, and efficacy of medicinal products throughout their shelf life. Reliable analytical methods are indispensable for the identification, quantification, and quality assessment of active pharmaceutical ingredients (APIs), impurities, and degradation products during drug development, manufacturing, and post-marketing surveillance. Among the various analytical techniques available, reverse-phase high-performance liquid chromatography (RP-HPLC) has become one of the most widely employed methods owing to its excellent selectivity, sensitivity, reproducibility, and suitability for routine pharmaceutical quality control [1, 9, 16, 20, 21]. Fluoroquinolones constitute an important class of broad-spectrum antibacterial agents extensively used in the treatment of bacterial infections. Balofloxacin, a third-generation fluoroquinolone antibiotic, exhibits potent antimicrobial activity against both Gram-positive and Gram-negative microorganisms by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby preventing bacterial DNA replication and cell division. Owing to its favorable pharmacokinetic profile, broad antibacterial spectrum, and therapeutic effectiveness, balofloxacin has gained considerable clinical importance in the treatment of respiratory tract infections, urinary tract infections, skin infections, and other susceptible bacterial diseases [6, 22–24, 40]. The therapeutic efficacy of pharmaceutical products largely depends on maintaining the chemical integrity and stability of the active pharmaceutical ingredient throughout manufacturing, transportation, storage, and distribution. Exposure to environmental factors such as heat, light, moisture, acidic or alkaline conditions, and oxidative agents may result in chemical degradation, leading to reduced drug potency, altered pharmacological activity, or the formation of potentially toxic degradation products. Consequently, regulatory agencies recommend the development of stability-indicating analytical methods capable of accurately quantifying the intact drug while effectively resolving degradation products generated under various stress conditions [2–5, 18, 19, 39]. Reverse-phase high-performance liquid chromatography has become the preferred analytical technique for pharmaceutical quality control because it provides rapid analysis, high resolution, excellent precision, and superior sensitivity for the simultaneous separation and quantification of pharmaceutical compounds and their related impurities. Furthermore, RP-HPLC methods are readily adaptable for routine industrial quality control and regulatory compliance because they can be validated according to internationally accepted guidelines. The flexibility of RP-HPLC in terms of column chemistry, mobile phase composition, detector selection, and optimization parameters makes it highly suitable for the analysis of complex pharmaceutical formulations [1, 9, 17, 20, 27, 36].

Several analytical techniques, including ultraviolet (UV) spectrophotometry, high-performance thin-layer chromatography (HPTLC), liquid chromatography–mass spectrometry (LC–MS), and RP-HPLC, have been reported for the estimation of balofloxacin in pharmaceutical dosage forms and biological matrices. Although these methods have demonstrated acceptable analytical performance, several reported procedures require lengthy chromatographic run times, complex mobile phase compositions, expensive instrumentation, or extensive sample preparation. In addition, many published methods lack comprehensive forced degradation studies and complete validation according to the International Council for Harmonisation (ICH) recommendations, thereby limiting their applicability as true stability-indicating methods for routine quality control analysis [6, 7, 22–26, 33]. According to the International Council for Harmonisation (ICH), analytical procedures intended for pharmaceutical quality control should be validated for specificity, system suitability, linearity, accuracy, precision, robustness, ruggedness, limit of detection, limit of quantification, and analytical range before they can be considered suitable for regulatory applications. Furthermore, forced degradation studies under acidic, alkaline, oxidative, thermal, photolytic, and neutral stress conditions are recommended to establish the stability-indicating capability of the developed analytical method. Such validation ensures that the analytical procedure consistently produces reliable, reproducible, and scientifically acceptable results suitable for routine pharmaceutical analysis and regulatory submissions [4, 5, 18, 19, 39]. Recent advancements in chromatographic science have focused on developing analytical methods that are not only accurate and precise but also rapid, economical, environmentally sustainable, and suitable for routine laboratory applications. Modern pharmaceutical industries increasingly require analytical procedures that reduce solvent consumption, shorten analysis time, improve chromatographic resolution, and provide enhanced reproducibility without compromising analytical performance. Consequently, considerable research efforts have been directed toward optimizing chromatographic parameters, including mobile phase composition, pH, stationary phase selection, flow rate, and detection wavelength, to achieve efficient and reliable analytical methods for pharmaceutical compounds [10, 11, 20, 21, 28, 30, 34, 35]. Although several analytical procedures for balofloxacin have been published, there remains a need for a simple, rapid, economical, robust, and fully validated RP-HPLC method capable of accurately estimating balofloxacin in bulk drug and tablet dosage forms while effectively separating degradation products generated under various stress conditions. Such a method would provide a practical analytical tool for routine quality control, stability testing, and regulatory evaluation in pharmaceutical industries and research laboratories [6, 7, 22–26, 40]. Therefore, the present investigation was undertaken to develop and validate a simple, rapid, accurate, precise, economical, and stability-indicating RP-HPLC method for the quantitative estimation of balofloxacin in bulk drug and pharmaceutical tablet dosage forms. The developed method was optimized by evaluating various chromatographic parameters, including mobile phase composition, pH, flow rate, and detection wavelength, and subsequently validated in accordance with ICH guidelines. Furthermore, forced degradation studies were performed under acidic, alkaline, oxidative, thermal, photolytic, and neutral stress conditions to establish the stability-indicating capability of the proposed analytical method and demonstrate its suitability for routine pharmaceutical quality control and stability assessment [4, 5, 18, 19, 39].

MATERIALS AND METHODS

2.1 Chemicals and Reagents

Parameter	Optimized Condition
Chromatographic system	Shimadzu LC-20 Binary Gradient HPLC
Detector	PDA Detector
Column	Qualisil BDS C18 (250 × 4.6 mm, 5 µm)
Mobile phase	Acetonitrile : 0.02 M Sodium Dihydrogen Phosphate Buffer (75:25, v/v)
Buffer pH	3.0 (adjusted with Orthophosphoric acid)
Flow rate	1.0 mL/min
Detection wavelength	293 nm
Injection volume	20 µL
Run time	10 min (or actual run time used)
Retention time	3.20 min
Column temperature	Ambient
Diluent	Methanol

Figure 1. Representative RP-HPLC chromatogram of balofloxacin standard obtained using acetonitrile: phosphate buffer (75:25, v/v; pH 3.0) as the mobile phase, showing a retention time (tR) of 3.20 min.

Sr. No.	Solvent System	Composition (v/v/v)	Rf BLF
1	chloroform: methanol	2.5:2.5	0.87 tailing
2	n-butanol: methanol	4:1	0.65 tailing
3	n-butanol: methanol: ammonia	2.5:1.5:1	0.75 tailing
4	n-butanol : methanol: ammonia	2.5:1:1.5	0.53

Figure3.2.1: Densitogram of standard BLF(Rf0.53±0.03), measuredat293nm, mobile phase n-butanol: methanol: ammonia (2.5: 1: 1.5 v/v/v).

Figure3.2.2: Calibration Curve of BLF; Y=14.462X+2532.5; Where, Correlation coefficient = 0.998, Slope = 14.462, Intercept=2532.5

Fig 3.2.3: Peak purity spectra of standard BLF (A), sample (B) extracted from a BLF tablet, scanned at the peak-start, peak-apex, and peak-end positions of the spot (correlation > 0.99)

Sr. No.	Concentration of BLF (µg/mL)	Peak Area (Mean±SD;n=6)	%RSD
	2	306891 ±1061.33	0.34
	4	482414 ±996.67	0.20
	6	670048 ±2373.12	0.35
	8	886579 ±1234.08	0.13
	10	1067745 ±1810.76	0.16
	12	1269769± 3491.43	0.27

Figure3.1.2:    Calibration Curve of Balofloxacin

CONCLUSION

A simple, rapid, accurate, precise, economical, and stability-indicating reverse-phase high-performance liquid chromatographic (RP-HPLC) method was successfully developed and validated for the quantitative estimation of balofloxacin in bulk drug and pharmaceutical tablet dosage forms. The chromatographic conditions were systematically optimized to achieve satisfactory peak resolution, acceptable retention time, excellent peak symmetry, and reproducible chromatographic performance. The developed analytical method was comprehensively validated according to the International Council for Harmonisation (ICH) guidelines for system suitability, specificity, linearity, accuracy, precision, robustness, ruggedness, limit of detection (LOD), and limit of quantification (LOQ), and all validation parameters complied with the recommended acceptance criteria. The proposed RP-HPLC method exhibited excellent linearity over the selected concentration range with a high correlation coefficient, while recovery studies confirmed the accuracy of the method and precision studies demonstrated excellent repeatability and intermediate precision with percentage relative standard deviation values well within acceptable limits. Robustness and ruggedness studies further established the reliability of the developed method under small deliberate variations in chromatographic conditions and routine laboratory environments. Forced degradation studies performed under acidic, alkaline, oxidative, thermal, photolytic, and neutral stress conditions demonstrated that the developed method effectively separated balofloxacin from its degradation products without interference, thereby confirming its stability-indicating capability. These findings indicate that the method is suitable for monitoring the stability of balofloxacin during pharmaceutical development, manufacturing, storage, and quality assurance studies. Overall, the validated RP-HPLC method is reliable, sensitive, cost-effective, and convenient for routine quantitative analysis of balofloxacin in bulk drug and pharmaceutical tablet dosage forms. Owing to its simplicity, short analysis time, excellent reproducibility, and compliance with ICH validation requirements, the proposed analytical method can be successfully employed for routine quality control testing, stability studies, regulatory submissions, and pharmaceutical research laboratories. Furthermore, the developed method may serve as a useful analytical tool for future formulation development and stability assessment of balofloxacin-containing pharmaceutical products.

REFERENCES

1. Ahuja, S., & Dong, M. W. (Eds.). (2005). Handbook of pharmaceutical analysis by HPLC. Elsevier Academic Press.
2. Bakshi, M., & Singh, S. (2002). Development of validated stability-indicating assay methods—Critical review. Journal of Pharmaceutical and Biomedical Analysis, 28(6), 1011–1040. https://doi.org/10.1016/S0731-7085(02)00047-X
3. Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. (2014). Development of forced degradation and stability-indicating studies of drugs—A review. Journal of Pharmaceutical Analysis, 4(3), 159–165. https://doi.org/10.1016/j.jpha.2013.09.003
4. International Council for Harmonisation. (2005). ICH Q2(R1): Validation of analytical procedures: Text and methodology. Geneva, Switzerland.
5. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products. Geneva, Switzerland.
6. Mathew, C., Ajitha, M., & Sathesh Babu, P. R. (2014). Development and validation of a stability-indicating RP-HPLC method for balofloxacin. Oriental Journal of Chemistry, 30(4), 1919–1923. https://doi.org/10.13005/OJC/300453
7. Patel, J., & Chokshi, A. (2014). Development and validation of stability-indicating RP-HPLC method for estimation of balofloxacin in bulk and tablet dosage form. International Journal of Pharmacy and Pharmaceutical Sciences, 6(8), 283–289.
8. Shabir, G. A. (2003). Validation of high-performance liquid chromatography methods for pharmaceutical analysis: Understanding the differences and similarities between validation requirements of the US FDA, the USP, and the ICH. Journal of Chromatography A, 987(1–2), 57–66. https://doi.org/10.1016/S0021-9673(02)01536-4
9. Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2010). Introduction to modern liquid chromatography (3rd ed.). John Wiley & Sons.
10. Skoog, D. A., Holler, F. J., & Crouch, S. R. (2018). Principles of instrumental analysis (7th ed.). Cengage Learning.
11. Swartz, M. E., & Krull, I. S. (2012). Analytical method development and validation. CRC Press.
12. Żuromska-Witek, B., Żmudzki, P., Szlósarczyk, M., Maślanka, A., & Hubicka, U. (2020). Development and validation of stability-indicating HPLC methods for the estimation of lomefloxacin and balofloxacin oxidation process under ACVA, H₂O₂, or KMnO₄ treatment: Kinetic evaluation and identification of degradation products by mass spectrometry. Molecules, 25(22), 5251. https://doi.org/10.3390/molecules25225251
13. Kumar, V., Bhutani, H., & Singh, S. (2007). ICH guidance in practice: Validated stability-indicating HPLC method for simultaneous determination of ampicillin and cloxacillin in combination drug products. Journal of Pharmaceutical and Biomedical Analysis, 43(2), 769–773. https://doi.org/10.1016/j.jpba.2006.07.051
14. Chakravarthy, V. A., Sailaja, B. B. V., & Kumar, A. P. (2015). Stability-indicating RP-HPLC method for simultaneous estimation of enrofloxacin and its degradation products in tablet dosage forms. Journal of Analytical Methods in Chemistry, 2015, Article 735145. https://doi.org/10.1155/2015/735145
15. United States Food and Drug Administration. (2015). Analytical procedures and methods validation for drugs and biologics: Guidance for industry.
16. Dong, M. W. (2006). Modern HPLC for practicing scientists. John Wiley & Sons.
17. Ermer, J., & Miller, J. H. M. (Eds.). (2005). Method validation in pharmaceutical analysis: A guide to best practice. Wiley-VCH.
18. European Medicines Agency. (2011). Guideline on bioanalytical method validation. European Medicines Agency.
19. International Council for Harmonisation. (2023). ICH Q2(R2): Validation of analytical procedures. International Council for Harmonisation.
20. Kazakevich, Y., & LoBrutto, R. (2007). HPLC for pharmaceutical scientists. John Wiley & Sons.
21. Meyer, V. R. (2010). Practical high-performance liquid chromatography (5th ed.). John Wiley & Sons.
22. Rao, R. N., Naidu, C. G., Suresh, C. V., Srinath, N., & Padiya, R. (2014). Ionic liquid based dispersive liquid–liquid microextraction followed by RP-HPLC determination of balofloxacin in rat serum. Analytical Methods, 6, 1674–1683. https://doi.org/10.1039/C3AY41826J
23. Ravisankar, P., Devadasu, C., Devala Rao, G., Gopal Reddy, P., Srinivasa Babu, P., & Shaik, A. B. (2013). A validated RP-HPLC method for the assay of balofloxacin in bulk and pharmaceutical dosage forms. International Journal of Chemical Sciences, 11(1), 553–568.
24. Samineni, R., Chimakurthy, J., Konidala, S. K., & Yamarthy, V. (2022). Development and validation of analytical method for estimation of balofloxacin in bulk and pharmaceutical dosage form by RP-HPLC. Research Journal of Pharmacy and Technology, 15(7), 2992–2996. https://doi.org/10.52711/0974-360X.2022.00499
25. Shaik, A. B. (2020). A novel validated RP-HPLC method for the determination of balofloxacin in bulk and pharmaceutical dosage forms. International Journal of Pharmaceutical Industry Research.
26. Sindhusri, M., Swetha, T., Ramadevi, A., & Ashok Kumar, A. (2015). A novel rapid RP-HPLC method development and validation for the quantitative estimation of balofloxacin in tablets. International Journal of Pharmacy and Pharmaceutical Sciences, 7(2), 319–322.
27. Snyder, L. R., Dolan, J. W., & Kirkland, J. J. (2012). Introduction to modern liquid chromatography (3rd ed.). John Wiley & Sons.
28. Swartz, M. E., & Krull, I. S. (2018). Analytical method development and validation. CRC Press.
29. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary (USP–NF). United States Pharmacopeial Convention.
30. Watson, D. G. (2012). Pharmaceutical analysis: A textbook for pharmacy students and pharmaceutical chemists (3rd ed.). Elsevier.
31. Bakshi, M., & Singh, S. (2002). Development of validated stability-indicating assay methods—Critical review. Journal of Pharmaceutical and Biomedical Analysis, 28(6), 1011–1040.
32. Blessy, M., Patel, R. D., Prajapati, P. N., & Agrawal, Y. K. (2014). Development of forced degradation and stability-indicating studies of drugs—A review. Journal of Pharmaceutical Analysis, 4(3), 159–165.
33. Nyola, N. K., & Govindasamy, J. (2012). Estimation of balofloxacin in active pharmaceutical ingredient and pharmaceutical formulations by different analytical methods. International Journal of Pharmaceutical Sciences and Research.
34. Gupta, S., Verma, P., Mishra, A. P., Omar, N., & Mathur, R. (2021). A review on novel analytical method development and validation by RP-HPLC method. Indian Journal of Forensic Medicine & Toxicology, 15(4), 3479–3486.
35. Skoog, D. A., Holler, F. J., & Crouch, S. R. (2018). Principles of instrumental analysis (7th ed.). Cengage Learning.
36. Snyder, L. R., Kirkland, J. J., & Glajch, J. L. (1997). Practical HPLC method development (2nd ed.). John Wiley & Sons.
37. British Pharmacopoeia Commission. (2024). British Pharmacopoeia 2024. The Stationery Office.
38. Indian Pharmacopoeia Commission. (2022). Indian Pharmacopoeia 2022. Ministry of Health and Family Welfare, Government of India.
39. United States Food and Drug Administration. (2015). Analytical procedures and methods validation for drugs and biologics: Guidance for industry.
40. Żuromska-Witek, B., Żmudzki, P., Szlósarczyk, M., Maślanka, A., & Hubicka, U. (2020). Development and validation of stability-indicating HPLC methods for the estimation of lomefloxacin and balofloxacin oxidation process under ACVA, H₂O₂, or KMnO₄ treatment: Kinetic evaluation and identification of degradation products by mass spectrometry. Molecules, 25(22), 5251. https://doi.org/10.3390/molecules25225251.